There have been a series of reports on the association of a genetic polymorphism at the cytochrome P450 CYP2D6 gene locus with cancer susceptibility. Many of these reports have remained contradictory either because of small numbers of patients studied or because of the limitations and controversy surrounding the pharmacokinetic assay used to identify affected individuals (poor metabolizers; PMs). We have recently developed a DNA-based assay that will allow the unequivocal identification of poor metabolizers and have applied this to the study of 1635 patients with different forms of cancer. Out of 361 lung cancer patients studied no statistically significant change in the proportion of PMs relative to controls was found. However, a significant increase in the proportion of poor metabolizers or heterozygotes was seen in leukaemia, bladder cancer and melanoma patients. This could be explained by a role for CYP2D6 in carcinogen detoxification or by linkage to another cancer-causing gene.

Oligonucleotide primers specific for intron 5 sequences were used to amplify a unique 718 bp fragment in the human GST mu gene. Using DNA from a panel of somatic cell hybrids it was possible to confirm the assignment of the GST1 locus to chromosome 1p and to refine localisation to 1p13 using Southern blot analysis of DNA from three-generation CEPH families and a GST mu specific DNA probe.